The expansion will serve to address increased demand for the company’s product development and manufacturing services
Open Book Extracts (OBX), an NSF, cGMP-certified manufacturer and distributor of the industry’s most advanced and highest quality cannabinoid ingredients and finished products, has announced expanded operations and service capabilities for finished goods manufacturing to serve their global customer base more effectively.
The new capabilities accelerate the pace of product innovation while significantly increasing the company’s manufacturing capacity and operational excellence.
Highlights of the expansion at the company’s headquarters in North Carolina include the addition of commercial equipment for high output production of tinctures, gummies and softgels, as well as packaging automation.
This expansion significantly enhances OBX’s ability to deliver its clients premium finished products with reduced lead times, and most importantly, within specification. Commercial production utilizing the expanded capabilities began in April 2022 with a soft introduction and is now being offered on all product lines.
The new capabilities support and enhance OBX’s existing concept-to-market formulation and manufacturing services, leveraging a broad portfolio of cannabinoid ingredients, including CBD, CBG, CBN, CBC, THCV and CBDV, alongside leading water soluble technology and unique delivery mechanisms to help clients commercialise a wide-range of finished goods, from core gummies, tinctures, softgels and capsules to beverages, tablets and aerosol sprays.
In support of the expansion, OBX has added more than 30 new team members, including the following key hires:
Additional key hires include Lakey Walker as master scheduler ((formerly with Santa Fe Natural Tobacco, manufacturer of the American Spirit brand), Sara O’Neal as quality control scientist (RTI International), Lee Puryear as finished goods quality assurance specialist (formerly with Gloster), and Jonathan Wetzel as sales and customer service associate (GVB Biopharma).
“The expansion of our team and finished goods capabilities is our solution to rising supply chain delays and inconsistency,” said Dave Neundorfer, OBX chief executive officer.
“This investment not only expands our customer-centric offerings to support future growth, but also builds upon our history of quality, customer service, and the realisation of our corporate mission to make products that work for the brands that care.”